30 results about "Hepatitis D" patented technology

It is disclosed a method for treating hepatitis B virus infection or hepatitis B virus / hepatitis delta virus co-infection, the method comprising administering to a subject in need of such treatment a first pharmaceutically acceptable agent that comprises at least one phosphorothioated nucleic acid polymer and a second pharmaceutically acceptable agent that comprises at least one nucleoside / nucleotide analog HBV polymerase inhibitor.

Disclosed herein are chimeric genes, compositions of chimeric genes, and compositions of polypeptides that are useful for the generation, enhancement, or improvement of an immune response to a target antigen. Some embodiments of the compositions include chimeric genes encoding hepatitis D antigen (HDAg) protein in combination with one or more self-cleavage 2A polypeptides and a preS 1 polypeptide. In certain embodiments the self-cleavage polypeptide is P2A.

The invention discloses an infectious cDNA clone of canine distemper virus CDV‑3 strain, a construction method and application thereof. In the present invention, the canine distemper virus CDV-3 strain is used as a template, and the full length of CDV-3 is divided into five fragments for RT-PCR amplification. After enzyme digestion and splicing, the 5 fragments were sequentially inserted into the eukaryotic vector, and the sequences of hammerhead ribozyme and hepatitis D ribozyme were added to the head of F1 and the end of F5, respectively, to obtain the infection of canine distemper virus CDV‑3 strain sex cDNA clones. Then, construct three helper plasmids expressing CDV-3N, P, L protein. The infectious cDNA clone of canine distemper virus CDV‑3 strain and three helper plasmids were co-transfected into 293T cells to obtain rescued recombinant CDV‑3 virus (rCDV‑3). The study found that rCDV‑3 viral titers were obtained up to 10 7.667 TCID 50 / mL, 10 times higher than wtCDV‑3. After infection of Vero cells with rCDV‑3, the highest virus titer was rapidly reached at 36 hours after infection, while the virus content of wtCDV‑3 reached the highest at 72 hours after infection. The proposal of the invention lays a foundation for the development of a novel vaccine against canine distemper virus and the study of its pathogenic mechanism.

A method and composition for treating a host infected with hepatitis D comprising administering an effective hepatitis D treatment amount of a described 2'-deoxy-beta-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof.

The invention provides a composition comprising an inhibitor of Na+-taurocholate cotransporting polypeptide (NTCP) and a active ingredient selected from the group consisting of a nucleoside analogue such as lamivudine, telbivudine, or entecavir, a nucleotide analogue such as tenofovir, adefovir and an immunomodulator such as interferon alpha. The NTCP inhibitor inhibits HBV / HDV entry into a cell and is preferably derived from an HBV pre-S1 peptide. Also provided are methods of treating HBV and HDV infection, hepatitis B and D, or chronic hepatitis B and D.

The present invention relates to hydrophobic modified preS-derived peptides of hepatitis B virus (HBV) which are derived from a HBV preS consensus sequence and are N-terminal preferably acylated and optional C-terminal modified. These hydrophobic modified preS-derived peptides of HBV are very effective HBV entry inhibitors as well as HDV entry inhibitors and are, thus, suitable for the inhibition of HBV and / or HDV infection, prevention of primary HBV and / or HDV infection as well as treatment of (chronic) hepatitis B and / or D. The present invention further relates to pharmaceutical and vaccine compositions comprising these hydrophobic modified preS-derived peptides of HBV.

The invention concerns the use of cyclophilin inhibitors in the treatment of Hepatitis B and Hepatitis D virus infections.